Abstract
Photodynamic therapy (PDT) has been approved by the U.S. Food and Drug Administration for the treatment of esophageal cancer, non-small cell lung cancer, Barrett’s esophagus, and age-related macular degeneration.1 – 6 Two types of PDT killing mechanisms are known to exist when utilizing light-activated photosensitizers (PSs) to generate reactive oxygen species that kill cancer cells. Type I PDT generates superoxide anion (O2−·) and other secondary oxygen species, such as hydroxyl radicals (HO·) or hydrogen peroxide (H2O2) for treatment.7 Many commonly used PSs are type II. Type II PDT is a complex process7 involving the interactions of the local photosensitizer concentration [PS], the local light fluence rate (intensity or ϕ), and the local oxygen concentration [O32] in order to produce singlet oxygen (O12). Furthermore, the local light fluence rate depends on light transmission through intervening tissue having local absorption coefficient, μa, and local reduced scattering coefficient, μs′. The complexity of the type II PDT process has made monitoring of treatments difficult and unreliable. Many clinical studies have not resulted in optimal treatment due to the lack of reliable dosimetry for singlet oxygen.6
Funding Information
  • National Institutes of Health (R44CA183236)

This publication has 49 references indexed in Scilit: